Replies to post #26156 on Anavex Life Sciences Corp (AVXL)

[GuiNoir]

I was able to understand the one sentence summary (sort of).

As to the rest I started getting oxidative stress and mitochondrial dysfunction so had to give up.

Maybe some day an app will translate these scientific articles into understandable English

[dayneyus]

If this Stuff Works for All these conditions....We're bigger then Apple. Looks like a Shotgun Blast:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=9,034,891&OS=9,034,891&RS=9,034,891


In some embodiments the disease or condition is selected from the group consisting of AD, Lewy body dementia, cerebral amyloid angiopathy (CAA), cerebral amyloidosis, fronto-temporal dementia, vascular dementia, hyperlipidemia, hypercholesterolemia, fronto-temporal dementia, vascular dementia, multiifract dementia (MID), stroke ischemia, MID combined with stroke/ischemia/head injury, combined MID and AD, mixed AD and PD, human head injury, age-associated memory impairments, mild cognitive impairment (MCI), MCI conducive to AD, bipolar disorder, mania, acute confusion disorder, attention deficit disorder, hallucinatory-paranoid states, emotional and attention disorders, post-operative delirium (anticholinergic syndrome following general anesthesia), antagonism of adverse effects (such as xerostomia, anomia, memory loss and/or confusion, psychosis) of tricyclic antidepressants or of certain drugs (e.g. trihexyphenidyl) used in treating schizophrenia and PD, schizophrenia, bipolar disorder, mania, tardive dyskinesia, congenital ornithine transcarbamylase deficiency, ollivopontocerebral atrophy, alcohol withdrawal symptoms, Huntington's chorea, Pick's disease, Friedrick's ataxia, Gilles de la Tourette disease, and Down's syndrome.


GSK3.beta.-mediated disorders; abnormalities in Wnt-signaling; a tau protein hyperphosphorylation-mediated damage, dysfunction or disease; endogenous growth factor-mediated diseases; a combination of risk factors for AD and/or one of the aforementioned diseases, e.g. head injury, oxidative stress, free radicals, apoptosis, inflammation, exogenous or endogenous toxins, excitotoxins, genetic predisposition, immune or autoimmune dysfunctions or diseases (e.g. lupus, multiple sclerosis, Sjogren's syndrome, chronic fatigue syndrome, fibromyalgia); and diseases states involving disturbances in which a cholinergic dysfunction has been implicated. In some embodiments the disease or condition is selected from the group consisting of AD, Lewy body dementia, cerebral amyloid angiopathy (CAA), cerebral amyloidosis, fronto-temporal dementia, vascular dementia, amyotrophic lateral sclerosis, hyperlipidemia, hypercholesterolemia, multiifract dementia (MID), stroke ischemia, MID combined with stroke/ischemia/head injury, combined MID and AD, mixed AD and PD, human head injury, age-associated memory impairments, mild cognitive impairment (MCI), MCI conducive to AD, bipolar disorder, mania, acute confusion disorder, attention deficit disorder, hallucinatory-paranoid states, emotional and attention disorders, post-operative delirium (anticholinergic syndrome following general anesthesia), antagonism of adverse effects (such as xerostomia, anomia, memory loss and/or confusion, psychosis) of tricyclic antidepressants or of certain drugs (e.g. trihexyphenidyl) used in treating schizophrenia and PD, schizophrenia, bipolar disorder, mania, tardive dyskinesia, congenital ornithine transcarbamylase deficiency, ollivopontocerebral atrophy, alcohol withdrawal symptoms, Huntington's chorea, Pick's disease, Friedrick's ataxia, Gilles de la Tourette disease, and Down's syndrome.